NCT04822337 2026-04-16
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Wake Forest University Health Sciences
Phase 1/2 Active not recruiting
Clinical Trials
49 trialsNCT03500445 2026-04-13
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
Phase 2 Active not recruiting
NCT00430365 2026-04-06
IFM2005-02
University Hospital, Toulouse
Phase 3 Completed
NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT02886065 2026-03-13
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04151667 2026-03-11
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04751877 2026-02-10
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT03702725 2026-01-06
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Phase 1 Completed
NCT07206810 2025-10-03
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Completed
NCT03314636 2025-08-08
CONPET
Oslo University Hospital
Phase 2 Active not recruiting
NCT04052880 2025-07-20
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT04891809 2025-04-10
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Active not recruiting
NCT06863584 2025-03-07
SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT00482261 2024-11-08
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT05248633 2024-06-05
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT03289299 2023-12-12
ASCENT
International Myeloma Foundation
Phase 2 Active not recruiting
NCT05280275 2023-12-01
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
Hellenic Society of Hematology
Phase 1/2 Unknown
NCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT03641456 2023-06-18
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Sun Yat-sen University
Phase 2 Unknown
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT00729118 2020-05-18
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01245673 2020-04-06
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
Phase 2 Completed
NCT00772915 2020-01-18
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT00477750 2019-10-11
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00687674 2019-08-20
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Terminated
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT01440582 2019-03-04
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00790842 2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2 Terminated
NCT01861340 2018-09-10
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed
NCT01042704 2017-07-31
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 1 Completed
NCT01816620 2017-04-25
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
Peking Union Medical College Hospital
Phase 2 Completed
NCT01985477 2016-09-14
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00698776 2016-06-21
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
Yale University
Phase 1 Completed
NCT01079936 2016-06-06
Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02041325 2016-05-17
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
Boston VA Research Institute, Inc.
Phase 2 Completed
NCT01501370 2016-05-10
ZLd_Ld
University of Turin, Italy
Phase 2 Withdrawn
NCT00567229 2015-11-20
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00445484 2015-08-24
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01531998 2015-06-19
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00564889 2013-05-14
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 2 Completed
NCT00478218 2011-08-31
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01002703 2011-08-12
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
University of Leipzig
Phase 1/2 Unknown
NCT00093028 2010-07-02
Study of Bortezomib and Revlimidâ„¢ for Patients Relapsing or Progressing on Total Therapy II
University of Arkansas
Phase 3 Completed